Agennix Announces Data From Talactoferrin Phase II Trial in Severe Sepsis
News Jan 24, 2011
Agennix AG has announced that new and more detailed data from a Phase II trial in severe sepsis with talactoferrin, an oral biologic therapy with immunomodulatory and antibacterial properties, will be presented at the 40th Critical Care Congress of the Society of Critical Care Medicine, to be held January 15-19, 2011 in San Diego, California.
Talactoferrin-related presentations are as follows:
"Talactoferrin alfa reduces 3 and 6 month all-cause mortality in patients with severe sepsis," will be part of the oral session, "Infectious Disease-Sepsis," to be held on January 16, 2011, 3:00-5:00 PM.
"Talactoferrin may confer increased survival in patients with septic shock and systolic cardiac dysfunction," will be presented as a poster presentation in the Therapeutics-Drugs and Pharmacokinetics-2 category.
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019